A Phase 3 clinical trial trial evaluating the safety and efficacy of dronabinol (oral) for the treatment of obstructive sleep apnea
Latest Information Update: 10 Aug 2020
Price :
$35 *
At a glance
- Drugs Dronabinol (Primary)
- Indications Sleep apnoea syndrome
- Focus Registrational; Therapeutic Use
- Sponsors RespireRx Pharmaceuticals
- 03 Aug 2020 According to a RespireRx Pharmaceuticals media release, pending the completion of a new formulation of dronabinol and an intended pre-IND meeting with the FDA, the company believes that it will be able to commence a pharmacokinetic study for the new formulation followed by phase III study for the treatment of OSA.
- 03 Jan 2019 RespireRx planning to proceed directly to a Phase 3 pivotal trial using the currently available dronabinol formulation (2.5, 5 and 10 mg gel caps)
- 19 Jun 2018 According to a RespireRx Pharmaceuticals media release, subjects to the outcome of an intended meeting with the FDA, the company will be able to commence this trial.